62 - Designing Robust Phase 3 Studies (S5E2)

All right, welcome back for another deep dive.
Today we're tackling a topic that's absolutely
crucial in the world of medicine. We're talking
about phase three clinical trials. You know,
those really big studies that determine whether
a new drug actually makes it to market or not.
Yeah, that's right. Phase three trials are kind
of the main event in drug development. There
are these large scale studies, randomized controlled,
really the gold standard for figuring out if
a new treatment is safe and effective. And for
this deep dive, we've got a whole bunch of sources
on everything from preclinical research all the
way to the regulations and even some statistics.
It's going to give us a really good understanding
of what makes a phase three trial truly robust.
We want to know what makes the results of these
trials trustworthy. Exactly, and today our goal
is to unpack these design principles. You know,
the things that make a phase three trial really
stand up to scrutiny. We're going to look at
statistical rigor, how they define the endpoints,
and why these choices are so important for getting
reliable evidence. Okay, so let's jump right
in. One of the first things that comes to mind
when we think about well -designed trials is
how patients are divided up. you know, who gets
the new treatment, who gets the standard treatment,
or a placebo. And that brings us to randomization
and control groups. They're kind of like the
foundation of these trials. Absolutely. Randomization,
it's all about minimizing bias. Friedman, Furberg,
and Demetz, they talk about this a lot in their
work. So when we randomly assign patients to
different groups, we try to make these groups
as similar as possible at the start of the trial.
Right. So it's not just about things we can see
like age or how severe their illness is. It's
about all those other factors that we might not
even know about that could affect the outcome.
Exactly. It's about leveling the playing field.
And there are even these more complex adaptive
randomization methods where the chance of being
assigned to a particular group can actually change
during the trial based on the data. That can
be really helpful in some cases, but also makes
the statistics more complicated. Oh, wow. I see.
So it's really important to get that balance
right between being efficient and making sure
the data is still solid. Now, what about control
groups? Ellison, Leprince, and Kugler, they really
emphasize control groups. Why are these so crucial?
Well, think of it like this. You need a point
of comparison, right? Without a control group,
it's like trying to judge a painting in a completely
dark room. You have no idea if the colors are
vibrant or dull, if the composition is good or
bad. The control group gives us that reference
point. We can see if the new treatment is truly
better than the existing standard of care or
even a placebo. It makes sense. You need that
benchmark to know if the new treatment is really
making a difference. Our sources also talk about
different trial designs, like parallel arm factorial
crossover. How do these designs affect the robustness
of a phase three trial? That's a great question.
The design of the trial has a huge impact on
how we analyze and understand the data. Bayer,
Piantadosi, and Sen, they've done a lot of work
on this. So in a parallel arm trial, you have
different groups running simultaneously, like
parallel tracks. Each group gets a different
treatment throughout the study. It's kind of
the most straightforward design. I see. So that's
the classic setup, where you have one group getting
the new drug, another group getting the standard
treatment, and maybe even a third group getting
a placebo. Exactly. Then you have factorial designs,
which are a bit more complex, but really interesting.
In a factorial design, you can actually test
multiple interventions or different doses of
the same drug at the same time. So it's like
running multiple trials within one trial. You
can even see how different treatments might interact
with each other. Oh, wow. get a lot more information
from one study. But that must make the analysis
pretty complicated. It does. It does. And then
there are crossover designs where participants
actually get different treatments in sequence.
So one person might get the new treatment first
and then the standard treatment or vice versa.
This can be helpful for reducing variability
because each person acts as their own control,
but you have to be careful about carryover effects
where one treatment might influence the effects
of the next one. That's interesting. So the way
you structure the trial itself is really important
for getting reliable answers. And of course,
we need to think about what we're actually measuring
to determine if the treatment is working. Let's
talk about endpoints. Endpoints, they're absolutely
crucial. They're the specific outcomes we're
looking at to see if the treatment is having
the desired effect. And Wang and Bakai, they
stress that these endpoints need to be clinically
relevant. They have to matter to patients. They
need to reflect a real benefit, like living longer
or having a better quality of life. So it's not
just about measuring something for the sake of
it. It has to translate to something meaningful
for the people who are actually taking the drug.
Exactly. And on top of that, endpoints have to
be measurable. We need a way to assess them in
a reliable and objective way. And there are different
types of endpoints. Oh, right. Our sources mentioned
continuous, binary, and time to event endpoints.
Can you give us a quick breakdown? Sure. So continuous
endpoints are things you can measure on a scale
like blood pressure or cholesterol levels. Binary
endpoints are events that either happen or don't,
like whether someone has a heart attack or not.
And time to event endpoints are things like overall
survival or the time it takes for a disease to
come back. They measure how long it takes for
a specific event to occur. So the choice of endpoint
really depends on what you're studying and what
you expect the treatment to do. Yeah, exactly.
You want to pick the endpoint that's most relevant
to the disease and the potential benefits of
the treatment. And then we have surrogate endpoints,
which we've talked about before in our preclinical
deep dive. They're like stand -ins for the real
clinical benefit. Right. They're those biomarkers
or measurements that we hope will predict a real
improvement in health. Exactly. And surrogate
endpoints can be really tempting because they
might show changes. earlier than the real clinical
outcome. But the key thing is that the link between
the surrogate endpoint and the actual clinical
benefit needs to be rock -solid. If that connection
is weak, then a drug that looks good based on
the surrogate might not actually help patients
in the long run. So while surrogate endpoints
can be useful as supporting evidence, they shouldn't
be the only basis for approval. Right. You want
to see a real impact on those direct clinically
meaningful endpoints. Okay, so let's move on
to the statistical side of things. One of the
most important aspects of a Phase 3 trial is
having enough participants. Why is sample size
so critical? Well, you need enough data to be
confident of the results. Right. Exactly. Wang,
Bokhai, and Yin, they all talk about how crucial
sample size is. If you don't have enough participants,
there's a risk of getting a false negative. That
means you might conclude that a treatment doesn't
work when it actually does. So it's about having
enough power to detect a real difference if one
exists. Yeah. You don't want to miss a potentially
effective treatment just because your study was
too small. And there are ways to calculate the
necessary sample size. How does that work? Well,
you need to consider a few things. First, how
big of an effect do you expect to see with the
new treatment? Then there's the variability of
the data. The more variability, the more participants
you need. And then there's the level of statistical
power you want. That's basically the probability
of correctly finding a real effect if it's there.
So it's like balancing all these factors to find
the sweet spot where you have enough data without
making the trial unnecessarily huge and expensive.
Exactly. Julius and Yin, they go into detail
about these sample size calculations. And there's
also the concept of sample size re -estimation,
which Gad talks about. That's where you might
adjust the sample size during the trial based
on the data you've already collected. So if it
looks like you need more participants to get
a clear answer, you can add them in. It sounds
like flexibility is important even in a phase
three trial. Now besides the statistics, the
way the trial is conducted and the data is handled
are also really important for the trial's robustness.
Oh, absolutely. We need really strong methodological
standards and rock -solid data integrity. Wang
and Makai are very clear about this. Every trial
needs a well -defined protocol that outlines
every detail of how the study will be run. Things
like how participants will be recruited, the
exact procedures for giving the treatment, how
data will be collected, everything. So it's like
a comprehensive instruction manual to ensure
consistency across all the different sites and
researchers involved. Exactly. And of course,
the data itself has to be top -notch. If the
data is flawed or incomplete, the conclusions
you draw from the trial are meaningless. make
sense. You can't build a house on a shaky foundation.
Our sources also mentioned good laboratory practices
or GLP and the importance of electronic signatures
and record linking. How do those fit into the
picture? So GLP is outlined in CFR Title 21,
Part 58, and it mainly governs those non -clinical
lab studies that happen before a drug even gets
to clinical trials. But the principles of GLP
quality, integrity, traceability, those apply
to every stage of drug development, including
phase three. Basically, you need to be sure that
the data you're basing your clinical trial on
is reliable. Oh, so it's all connected. The quality
of the early data influences the quality of the
later data. Exactly. And electronic signatures
and record linking, they play a crucial role
in ensuring that the electronic data from the
trial is accurate, reliable, and can't be tampered
with. You can track every change, every edit,
every piece of data. That's outlined in CFR Title
21, Part 11. So it's all about creating an audit
trail and preventing data manipulation. So it's
a whole system of checks and balances to maintain
the integrity of the data. Now, even with all
these safeguards in place, I imagine there can
still be unexpected challenges when you're running
a huge Phase 3 trial. Oh, definitely. Yin and
Halaby talk about how, even with the best planning,
things can pop up that you didn't anticipate.
Adaptive designs, which are more common in earlier
phases, can sometimes be used in phase three,
but you have to be really careful because you
don't want to compromise the integrity of the
primary analysis. So there's a balance between
being flexible and sticking to the plan. Yeah.
And then there's the cost factor. Turner points
out that phase three trials are incredibly expensive,
so pharmaceutical companies need to weigh those
costs against the potential benefits of the new
treatment. It's a huge investment of time and
resources. So to sum it all up, what are the
key ingredients of a robust and reliable phase
three trial? I'd say the most important things
are randomization and appropriate control groups
to minimize bias and isolate the effect of the
treatment. Then you need clinically meaningful
endpoints that are measurable in a reliable way.
And of course you need enough participants to
have the statistical power to detect a real effect
if it exists. And finally, rigorous methodology
and unwavering data integrity throughout the
entire trial are absolutely essential. Those
are the pillars that support the whole structure.
It's fascinating to see how all these different
elements work together to generate the evidence.
that drives medical progress. It is. It's like
a puzzle where each piece is critical to the
overall picture. And ultimately, it's about getting
those new treatments to the people who need them.
Absolutely. Well, thanks for this deep dive.
It's been incredibly insightful to explore the
world of phase three trials and see the level
of detail and care that goes into designing them.
My pleasure. It's always great to talk about
the science behind drug development. And to our
listeners, we hope you found this deep dive informative
and maybe even a little bit inspiring. It's a
reminder that even in a world of complex science,
there are clear principles and careful processes
that guide the search for new and effective therapies.
So until next time, keep asking those questions
and keep diving deep.